Browse by category

Research presented at this year’s European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) shows that those living with obstructive sleep apnoea (OSA) have a 71% higher risk of cardiovascular events (CVEs) or death from any cause (all-cause mortality) compared with those not living with OSA. OSA is characterised by recurrent upper airway obstruction during sleep and is associated with reduced quality of sleep and life and increased cardiovascular risk. The preval

Apnimed has announced positive topline results from its second pivotal Phase 3 clinical trial – LunAIRo - of Apnimed's lead candidate...

Sleep medicine professionals favour continuous positive airway pressure therapy as treatment for comorbid obesity and obstructive sleep...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Patients with moderate to severe sleep apnoea for people who failed to adapt or are not suited to continuous positive pressure airway...

People suffering with obstructive sleep apnoea (OSA) can reduce their risk of dying from cardiovascular disease if they use a continuous...